Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known… FDA label
Genvoya · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Genvoya | EXPERIMENTAL | Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days |
| Name | Type | Description |
|---|---|---|
| Genvoya | DRUG | Oral use (one tablet each day); 150/150/200/10 mg; 28 days |
Inclusion Criteria: * an age above 18 years * consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) * indication for HIV post-exposure prophylaxis (according to French guidelines) * person able to understand the nature of the study * person who signed his conse...
Genvoya is a small molecule medicine developed by Gilead Sciences, Inc. (ticker GILD) for HIV risk. It has been studied in a Phase 3 clinical trial in France evaluating compliance with treatment when used as HIV post-exposure prophylaxis in adults aged 18 years and older.
Genvoya was studied for HIV post-exposure prophylaxis, a preventive use in people at risk of HIV exposure. The Phase 3 trial NCT02998320 evaluated how well participants complied with treatment when Genvoya was given in this setting. The study enrolled 101 adults in France.
Genvoya is made by Gilead Sciences, Inc., which trades under the ticker GILD. Gilead is the developer associated with the clinical program for Genvoya in HIV risk.
Genvoya has been evaluated in a Phase 3 clinical trial for HIV risk. The trial, NCT02998320, is listed as completed. Genvoya is an investigational use in this prevention setting and is not described as approved for this indication.
Genvoya has been studied in the Phase 3 trial NCT02998320, titled Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis. The trial was completed, enrolled 101 participants, was conducted in France, and included adults aged 18 years and older.
The Phase 3 trial NCT02998320 was an uncontrolled study, meaning it did not use a randomized or double-blind design. It enrolled 101 adults aged 18 years and older in France and assessed compliance with Genvoya treatment when used as HIV post-exposure prophylaxis.